These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 33474638)
1. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. Perez-Diaz-Del-Campo N; Marin-Alejandre BA; Cantero I; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Riezu-Boj JI; Milagro FI; Tur JA; Martinez JA; Abete I; Zulet MA Eur J Nutr; 2021 Sep; 60(6):3043-3057. PubMed ID: 33474638 [TBL] [Abstract][Full Text] [Related]
2. Association of the Perez-Diaz-Del-Campo N; Abete I; Cantero I; Marin-Alejandre BA; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Riezu-Boj JI; Milagro FI; Tur JA; Martinez JA; Zulet MA Nutrients; 2020 Apr; 12(5):. PubMed ID: 32365683 [TBL] [Abstract][Full Text] [Related]
3. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Marin-Alejandre BA; Abete I; Cantero I; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Quiroga J; Martinez-Echeverria A; Uriz-Otano JI; Huarte-Muniesa MP; Tur JA; Martinez JA; Zulet MA Nutrients; 2019 Oct; 11(10):. PubMed ID: 31652512 [TBL] [Abstract][Full Text] [Related]
4. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Marin-Alejandre BA; Cantero I; Perez-Diaz-Del-Campo N; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Quiroga J; Martinez-Echeverria A; Uriz-Otano JI; Huarte-Muniesa MP; Tur JA; Martinez JA; Abete I; Zulet MA Liver Int; 2021 Jul; 41(7):1532-1544. PubMed ID: 33550706 [TBL] [Abstract][Full Text] [Related]
5. Association between Different Animal Protein Sources and Liver Status in Obese Subjects with Non-Alcoholic Fatty Liver Disease: Fatty Liver in Obesity (FLiO) Study. Recaredo G; Marin-Alejandre BA; Cantero I; Monreal JI; Herrero JI; Benito-Boillos A; Elorz M; Tur JA; Martínez JA; Zulet MA; Abete I Nutrients; 2019 Oct; 11(10):. PubMed ID: 31623368 [TBL] [Abstract][Full Text] [Related]
6. Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study. Marin-Alejandre BA; Abete I; Monreal JI; Elorz M; Benito-Boillos A; Herrero JI; Navarro-Blasco I; Tur JA; Bandarra NM; Zulet MA; Martinez JA J Clin Lipidol; 2020; 14(6):837-849.e2. PubMed ID: 32962964 [TBL] [Abstract][Full Text] [Related]
7. A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers. Perez-Diaz-Del-Campo N; Riezu-Boj JI; Marin-Alejandre BA; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Milagro FI; Bugianesi E; Tur JA; Martinez JA; Abete I; Zulet MA Panminerva Med; 2022 Dec; 64(4):485-496. PubMed ID: 35437302 [TBL] [Abstract][Full Text] [Related]
8. Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults. Cantero I; Elorz M; Abete I; Marin BA; Herrero JI; Monreal JI; Benito A; Quiroga J; Martínez A; Huarte MP; Uriz-Otano JI; Tur JA; Kearney J; Martinez JA; Zulet MA Int J Med Sci; 2019; 16(1):75-83. PubMed ID: 30662331 [TBL] [Abstract][Full Text] [Related]
9. Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. Perez-Diaz-Del-Campo N; Riezu-Boj JI; Marin-Alejandre BA; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Milagro FI; Tur JA; Abete I; Zulet MA; Martinez JA Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34199237 [TBL] [Abstract][Full Text] [Related]
10. Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study. Galarregui C; Cantero I; Marin-Alejandre BA; Monreal JI; Elorz M; Benito-Boillos A; Herrero JI; de la O V; Ruiz-Canela M; Hermsdorff HHM; Bressan J; Tur JA; Martínez JA; Zulet MA; Abete I Eur J Nutr; 2021 Jun; 60(4):1769-1780. PubMed ID: 32857176 [TBL] [Abstract][Full Text] [Related]
11. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. Friedrich D; Marschall HU; Lammert F BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129 [TBL] [Abstract][Full Text] [Related]
12. Fruit Fiber Consumption Specifically Improves Liver Health Status in Obese Subjects under Energy Restriction. Cantero I; Abete I; Monreal JI; Martinez JA; Zulet MA Nutrients; 2017 Jun; 9(7):. PubMed ID: 28657604 [TBL] [Abstract][Full Text] [Related]
13. Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: A pilot, randomized trial. Goss AM; Dowla S; Pendergrass M; Ashraf A; Bolding M; Morrison S; Amerson A; Soleymani T; Gower B Pediatr Obes; 2020 Jul; 15(7):e12630. PubMed ID: 32128995 [TBL] [Abstract][Full Text] [Related]
14. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Pataky Z; Genton L; Spahr L; Lazarevic V; Terraz S; Gaïa N; Rubbia-Brandt L; Golay A; Schrenzel J; Pichard C Dig Dis Sci; 2016 Sep; 61(9):2721-31. PubMed ID: 27142672 [TBL] [Abstract][Full Text] [Related]
15. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial. Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890 [TBL] [Abstract][Full Text] [Related]